Toxicity of clindamycin as prophylaxis for AIDS-associated toxoplasmic encephalitis. Community Programs for Clinical Research on AIDS.
A double-blind, placebo-controlled trial was set up to compare clindamycin and pyrimethamine as prophylaxis for toxoplasmic encephalitis (TE) in HIV-infected patients at risk of the disorder. Interim analysis showed that clindamycin-treated patients were 4.4 (95% confidence interval 1.3-15.2) times more likely to experience an adverse effect that necessitated withdrawal of the study drug than those who received placebo. Diarrhoea and rash were reported in 16 (31%) and 11 (21%), respectively, of 52 patients treated with clindamycin (300 mg twice daily) compared with 2 (6%; p = 0.06) and none (p = 0.01) of the 32 placebo-treated patients. The clindamycin arm of the trial was prematurely terminated, although recruitment to the pyrimethamine arm continues.
Department of Medicine, University of California, San Francisco.
M A
MA
Jacobson
C L
CL
Besch
C
C
Child
R
R
Hafner
J P
JP
Matts
K
K
Muth
D N
DN
Wentworth
L
L
Deyton
D000163:Acquired Immunodeficiency Syndrome / Q000150:complications*; D000328:Adult; D000818:Animals; D002981:Clindamycin / Q000009:adverse effects*; D004311:Double-Blind Method; D004660:Encephalitis / Q000150:complications / Q000517:prevention & control*; D005260:Female; D006801:Humans; D008297:Male; D011739:Pyrimethamine / Q000627:therapeutic use; D014122:Toxoplasma
D002981:Clindamycin; D011739:Pyrimethamine